Medindia

X

Reportlinker Adds New Developments in Treating Genetic Disorders: The Global Market

Wednesday, April 7, 2010 Genetics & Stem Cells News J E 4
Advertisement


NEW YORK, April 6 Reportlinker.com announces that a new market research report is available in its catalogue:

New Developments in Treating Genetic Disorders: The Global Market

http://www.reportlinker.com/p0185999/New-Developments-in-Treating-Genetic-Disorders-The-Global-Market.html

THIS REPORT:

Discussion of treatment options, key products and new developments in therapies for such genetic disorders as cystic fibrosis, Gaucher disease, hemophilia, Huntington's disease, sickle-cell disease, and Tay-Sachs disease

Analysis of the market, citing data for 2008, estimates for 2009, and projections, with 5-year compound annual growth rates (CAGRs), through 2014

Examination of the market in chromosomal disorders, such as Down, Klinefelter's, Prader-Willi, and Turner's syndromes

Patent evaluations and company profiles.

Chapter- 1: INTRODUCTION

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THE STUDY 1

SCOPE OF REPORT 1

METHODOLOGY 2

ANALYST CREDENTIALS 2

RELATED BCC STUDIES 3

BCC ONLINE SERVICES 3

DISCLAIMER 3

Chapter-2: SUMMARY

GENETIC DISORDER MARKETS: MAJOR MARKETS SUMMARY 4

SUMMARY TABLE A GLOBAL GENETIC DISORDER PRODUCT REVENUES BY MAJOR MARKET SEGMENT, THROUGH 2014 ($ MILLIONS) 5

SUMMARY FIGURE GLOBAL GENETIC DISORDER PRODUCT REVENUES, 2007-2014 ($ MILLIONS) 5

LEADING MANUFACTURERS 5

SUMMARY TABLE B TOTAL COMPANY SALES FOR GENETIC DISORDER TREATMENT, 2009 ($ MILLIONS) 6

Chapter-3: INDUSTRY OVERVIEW

INTRODUCTION 7

HISTORY OF GENETIC RESEARCH 7

OVERVIEW OF DNA AND GENES 7

THE HUMAN GENOME PROJECT 8

HAPMAP PROJECT 9

TERMINOLOGY 9

TABLE 1 GLOSSARY OF GENETIC TERMS 9

TABLE 1 (CONTINUED) 10

TABLE 1 (CONTINUED) 11

TABLE 1 (CONTINUED) 12

TABLE 1 (CONTINUED) 13

TABLE 1 (CONTINUED) 14

TABLE 1 (CONTINUED) 15

TABLE 1 (CONTINUED) 16

GENES AND FAMILY HISTORY 16

OVERVIEW OF GENETIC DISORDERS 16

GENE MUTATIONS 16

CAUSES OF GENE MUTATIONS 17

GENETIC TESTING AND SCREENING 18

TESTING POPULATION GROUPS (ETHNOGENETICS) 19

DIRECT TO CONSUMER GENETIC TESTING 19

U.S. DEMOGRAPHICS 20

TABLE 2 NUMBER OF BIRTHS IN THE U.S., 2006-2010 21

TABLE 3 POPULATION GROWTH AND BIRTH STATISTICS U.S., 2011-2020 (THOUSANDS) 21

FIGURE 1 POPULATION GROWTH AND BIRTH STATISTICS U.S. 2011-2020 (THOUSANDS) 22

INTERNATIONAL DEMOGRAPHICS 23

TABLE 4 ESTIMATED WORLD POPULATION AND ANNUAL GROWTH BY SELECTED AGE GROUP AND SELECTED YEARS, 2000 THROUGH 2030 (MILLIONS) 23

FIGURE 2 ESTIMATED WORLD POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS, 2000-2030 (MILLIONS) 23

TABLE 5 WORLD POPULATION BY SELECTED COUNTRIES, THROUGH 2014 (MILLIONS) 24

FIGURE 3 WORLD POPULATION BY SELECTED COUNTRIES, 2007-2014 (MILLIONS) 25

INTERNATIONAL BIRTH RATE STATISTICS 25

TABLE 6 BIRTHS FOR SELECTED COUNTRIES, 1995-2015 (THOUSANDS) 26

FIGURE 4 BIRTHS FOR SELECTED COUNTRIES, 1995-2015 (THOUSANDS) 26

Chapter-4: ISSUES AFFECTING THE MARKET

GENETIC RESEARCH 27

GENE THERAPY COMPARED TO CELL THERAPY 27

ISSUES WITH HUMAN CLONING 28

LEGISLATIVE ISSUES 28

THE GENETIC INFORMATION NONDISCRIMINATION ACT (GINA) 28

GERMAN LEGISLATION 29

AUSTRALIAN GENETIC TESTING LAW 29

EUROPEAN UNION ACTION IN THE FIELD OF RARE DISEASES 30

GENETICS CLINICS 30

TABLE 7 NUMBER OF GENETIC CLINICS BY COUNTRY 31

GENOME SEQUENCING TECHNOLOGY 31

TECHNOLOGICAL APPLICATIONS OF GENOME SEQUENCING 32

SEQUENCING COSTS 32

Chapter-5: GENE MUTATION DISORDERS

DESCRIPTIONS OF GENE MUTATION DISORDERS 33

CYSTIC FIBROSIS 33

Treatment Options 34

Key Products 34

TABLE 8 PHARMACEUTICAL TREATMENTS FOR CYSTIC FIBROSIS 34

New Developments 34

New Developments (Continued) 35

TABLE 9 CYSTIC FIBROSIS DEVELOPMENTS BY PHASE OF DEVELOPMENT 36

TABLE 9 (CONTINUED) 37

FABRY DISEASE 37

Treatment Options 37

Key Products 38

TABLE 10 PHARMACEUTICAL TREATMENTS FOR FABRY DISEASE 38

New Developments 38

TABLE 11 FABRY DISEASE DEVELOPMENTS BY PHASE OF DEVELOPMENT 38

GAUCHER'S DISEASE 39

Treatment Options 39

Key Products 40

TABLE 12 PHARMACEUTICAL TREATMENTS FOR GAUCHER'S DISEASE 40

New Developments 40

TABLE 13 GAUCHER'S DISEASE DEVELOPMENTS BY PHASE OF DEVELOPMENT 41

HEMOPHILIA AND OTHER INHERITED BLEEDING DISORDERS 41

Treatment Options 41

Key Products 41

Key Products (Continued) 42

TABLE 14 BIOLOGICAL AND PHARMACEUTICAL TREATMENTS FOR HEMOPHILIA AND OTHERS 43

TABLE 15 EXPANDED INDICATIONS AND PRODUCT CHANGES 2005-2009 44

New Developments 45

TABLE 16 HEMOPHILIA AND RELATED BLOOD DISORDER DEVELOPMENTS BY PHASE OF DEVELOPMENT 46

HUNTINGTON'S DISEASE 46

Treatment Options 47

Key Products 47

TABLE 17 PHARMACEUTICAL TREATMENTS FOR HUNTINGTON'S DISEASE 47

New Developments 48

TABLE 18 HUNTINGTON'S DISEASE DEVELOPMENTS BY PHASE OF DEVELOPMENT 48

HUNTER SYNDROME 48

Treatment Options 49

Key Products 49

TABLE 19 PHARMACEUTICAL TREATMENTS FOR HUNTER SYNDROME 49

New Developments 49

TABLE 20 HUNTER SYNDROME DEVELOPMENTS BY PHASE OF DEVELOPMENT 50

HURLER SYNDROME 50

Treatment Options 50

Key Products 51

TABLE 21 PHARMACEUTICAL TREATMENTS FOR HURLER SYNDROME 51

New Developments 51

MAROTEAUX-LAMY SYNDROME 51

Treatment Options 51

Key Products 52

TABLE 22 PHARMACEUTICAL TREATMENTS FOR MAROTEAUX-LAMY SYNDROME 52

PHENYLKETONURIA (PKU) 52

Treatment Options 53

Key Products 53

TABLE 23 PHARMACEUTICAL TREATMENTS FOR PKU 53

New Developments 54

TABLE 24 PKU DEVELOPMENTS BY PHASE OF DEVELOPMENT 54

POMPE DISEASE 54

Treatment Options 54

Key Products 55

TABLE 25 PHARMACEUTICAL TREATMENTS FOR POMPE DISEASE 55

New Developments 55

TABLE 26 POMPE DISEASE DEVELOPMENTS BY PHASE OF DEVELOPMENT 55

SICKLE CELL DISEASE 55

Treatment Options 56

Key Products 56

TABLE 27 PHARMACEUTICAL TREATMENTS FOR SICKLE CELL DISEASE 57

New Developments 57

TABLE 28 SICKLE CELL DISEASE DEVELOPMENTS BY PHASE OF DEVELOPMENT 57

TAY-SACHS DISEASE 57

Treatment Options 58

Key Products 58

New Developments 58

TABLE 29 TAY-SACHS DISEASE DEVELOPMENTS BY PHASE OF DEVELOPMENT 59

WILSON'S DISEASE 59

Treatment Options 59

Key Products 59

TABLE 30 PHARMACEUTICAL TREATMENTS FOR WILSON'S DISEASE 60

New Developments 60

TABLE 31 WILSON'S DISEASE DEVELOPMENTS BY PHASE OF DEVELOPMENT 61

OTHER APPROVED PRODUCTS FOR RARE GENETIC DISORDERS 61

OTHER NEW DEVELOPMENT PROJECTS 61

PHASE II 61

PHASE I 62

PRECLINICAL 62

MUSCULAR DYSTROPHY FOCUS: PRECLINICAL THROUGH PHASE III 63

AVI-4658 63

AVI-5038 64

Catena/Sovrima 64

PRO044 64

PTC-124 64

SNT-317/omigapil 64

STATISTICS 65

CYSTIC FIBROSIS 65

TABLE 32 CYSTIC FIBROSIS STATISTICS 65

GAUCHER'S DISEASE 65

TABLE 33 GAUCHER'S DISEASE STATISTICS 66

PHENYLKETONURIA 66

TAY-SACHS DISEASE 66

TABLE 34 TAY-SACHS DISEASE STATISTICS 67

SICKLE CELL DISEASE 67

TABLE 35 SICKLE-CELL DISEASE STATISTICS 67

HEMOPHILIA 67

HUNTINGTON'S DISEASE 68

MARKET SIZE AND GROWTH 68

TABLE 36 GLOBAL GENE MUTATION PRODUCT REVENUES BY DISORDER THROUGH 2014 ($ MILLIONS) 69

FIGURE 5 GLOBAL GENE MUTATION PRODUCT REVENUES BY DISORDER, 2007-2014 ($ MILLIONS) 70

COMPETITIVE STRUCTURE AND MARKET SHARE 70

CYSTIC FIBROSIS MARKET 70

TABLE 37 GLOBAL PRODUCT REVENUES FOR CYSTIC FIBROSIS TREATMENTS BY MANUFACTURER, THROUGH 2014 ($ MILLIONS) 71

FIGURE 6 GLOBAL PRODUCT REVENUES FOR CYSTIC FIBROSIS TREATMENTS BY MANUFACTURER, 2007-2014 ($ MILLIONS) 72

FABRY DISEASE MARKET 72

TABLE 38 GLOBAL PRODUCT REVENUES FOR FABRY DISEASE TREATMENTS BY MANUFACTURER, THROUGH 2014 ($ MILLIONS) 73

FIGURE 7 GLOBAL PRODUCT REVENUES FOR FABRY DISEASE TREATMENTS BY MANUFACTURER, 2007-2014 ($ MILLIONS) 73

GAUCHER'S DISEASE MARKET 74

TABLE 39 GLOBAL PRODUCT REVENUES FOR GAUCHER'S DISEASE TREATMENTS BY MANUFACTURER, THROUGH 2014 ($ MILLIONS) 74

FIGURE 8 GLOBAL PRODUCT REVENUES FOR GAUCHER'S DISEASE TREATMENTS BY MANUFACTURER, 2007-2014 ($ MILLIONS) 75

HEMOPHILIA AND RELATED BLOOD DISORDER MARKET 75

Hemophilia and Related Blood ... (Continued) 76

TABLE 40 GLOBAL PRODUCT REVENUES FOR HEMOPHILIA TREATMENTS BY MANUFACTURER, THROUGH 2014 ($ MILLIONS) 77

FIGURE 9 GLOBAL PRODUCT REVENUES FOR HEMOPHILIA TREATMENTS BY MANUFACTURER, 2007-2014 ($ MILLIONS) 77

HUNTINGTON'S DISEASE MARKET 78

TABLE 41 GLOBAL PRODUCT REVENUES FOR HUNTINGTON'S DISEASE TREATMENTS BY MANUFACTURER, THROUGH 2014 ($ MILLIONS) 78

FIGURE 10 GLOBAL PRODUCT REVENUES FOR HUNTINGTON'S DISEASE TREATMENTS BY MANUFACTURER, 2007-2014 ($ MILLIONS) 79

HUNTER SYNDROME MARKET 79

TABLE 42 GLOBAL PRODUCT REVENUES FOR HUNTER SYNDROME TREATMENTS BY MANUFACTURER, THROUGH 2014 ($ MILLIONS) 80

FIGURE 11 GLOBAL PRODUCT REVENUES FOR HUNTER SYNDROME TREATMENTS BY MANUFACTURER, 2007-2014 ($ MILLIONS) 80

HURLER SYNDROME MARKET 80

TABLE 43 GLOBAL PRODUCT REVENUES FOR HURLER SYNDROME TREATMENTS BY MANUFACTURER, THROUGH 2014 ($ MILLIONS) 81

FIGURE 12 GLOBAL PRODUCT REVENUES FOR HURLER SYNDROME TREATMENTS BY MANUFACTURER, 2007-2014 ($ MILLIONS) 81

MAROTEAUX-LAMY SYNDROME MARKET 81

TABLE 44 GLOBAL PRODUCT REVENUES FOR MAROTEAUX-LAMY SYNDROME TREATMENTS BY MANUFACTURER, THROUGH 2014 ($ MILLIONS) 82

FIGURE 13 GLOBAL PRODUCT REVENUES FOR MAROTEAUX-LAMY SYNDROME TREATMENTS BY MANUFACTURER, 2007-2014 ($ MILLIONS) 82

PHENYLKETONURIA (PKU) MARKET 83

TABLE 45 GLOBAL PRODUCT REVENUES FOR PKU TREATMENTS BY MANUFACTURER, THROUGH 2014 ($ MILLIONS) 83

FIGURE 14 GLOBAL PRODUCT REVENUES FOR PKU TREATMENTS BY MANUFACTURER, 2007-2014 ($ MILLIONS) 83

POMPE DISEASE MARKET 84

TABLE 46 GLOBAL PRODUCT REVENUES FOR POMPE DISEASE TREATMENTS BY MANUFACTURER, THROUGH 2014 ($ MILLIONS) 84

FIGURE 15 GLOBAL PRODUCT REVENUES FOR POMPE DISEASE TREATMENTS BY MANUFACTURER, 2007-2014 ($ MILLIONS) 84

Chapter-6: CHROMOSONAL DISORDERS

DESCRIPTIONS OF CHROMOSONAL DISORDERS 85

DOWN SYNDROME 85

Treatment Options 85

New Developments 86

TABLE 47 DOWN SYNDROME DEVELOPMENTS BY PHASE OF DEVELOPMENT 86

KLINEFELTER SYNDROME 86

Treatment Options 87

Key Products 87

TABLE 48 EXAMPLES OF PHARMACEUTICAL TREATMENTS FOR KLINEFELTER SYNDROME 87

New Developments 88

TABLE 49 EXAMPLES OF TESTOSTERONE REPLACEMENT DEVELOPMENTS BY PHASE OF DEVELOPMENT 88

PRADER-WILLI SYNDROME 88

Treatment Options 88

Key Products 89

TABLE 50 PHARMACEUTICAL TREATMENTS FOR PRADER-WILLI SYNDROME 89

New Developments 89

TURNER SYNDROME 90

Treatment Options 90

Key Products 91

TABLE 51 FDA APPROVED BIOPHARMACEUTICAL TREATMENTS FOR TURNER'S SYNDROME 92

TABLE 51 (CONTINUED) 93

New Developments 93

TABLE 52 TURNER SYNDROME DEVELOPMENTS BY PHASE OF DEVELOPMENT 93

STATISTICS 93

DOWN SYNDROME 93

TABLE 53 DOWN SYNDROME RISK AS A COMPARISON TO MATERNAL AGE 94

KLINEFELTER SYNDROME 94

PRADER-WILLI SYNDROME 94

TURNER SYNDROME 94

MARKET SIZE AND GROWTH 94

TABLE 54 GLOBAL CHROMOSONAL DISORDER PRODUCT REVENUES* BY DISORDER, THROUGH 2014 ($ MILLIONS) 95

FIGURE 16 GLOBAL CHROMOSONAL DISORDER PRODUCT REVENUES BY DISORDER, 2007-2014 ($ MILLIONS) 95

COMPETITIVE STRUCTURE AND MARKET SHARE 96

KLINEFELTER SYNDROME 96

TABLE 55 GLOBAL PRODUCT REVENUES FOR KLINEFELTER SYNDROME TREATMENTS, THROUGH 2014 ($ MILLIONS) 96

FIGURE 17 GLOBAL PRODUCT REVENUES FOR KLINEFELTER SYNDROME TREATMENTS BY MANUFACTURER, 2007-2014 ($ MILLIONS) 97

PRADER-WILLI SYNDROME 97

TABLE 56 GLOBAL PRODUCT REVENUES* FOR PRADER-WILLI SYNDROME TREATMENTS BY MANUFACTURER, THROUGH 2014 ($ MILLIONS) 98

FIGURE 18 GLOBAL PRODUCT REVENUES FOR PRADER-WILLI SYNDROME TREATMENTS BY MANUFACTURER, 2007-2014 ($ MILLIONS) 98

TURNER'S SYNDROME 98

TABLE 57 GLOBAL PRODUCT REVENUES* FOR TURNER'S SYNDROME TREATMENTS BY MANUFACTURER, THROUGH 2014 ($ MILLIONS) 99

FIGURE 19 GLOBAL PRODUCT REVENUES FOR TURNER'S SYNDROME TREATMENTS BY MANUFACTURER, 2007-2014 ($ MILLIONS) 100

Chapter-7: MARKET SUMMARY

TOTAL GLOBAL MARKET FOR GENETIC DISORDERS 101

TABLE 58 GLOBAL GENETIC DISORDER PRODUCT REVENUES BY MAJOR MARKET SEGMENT, THROUGH 2014 ($ MILLIONS) 101

FIGURE 20 GLOBAL GENETIC DISORDER PRODUCT REVENUES BY MAJOR MARKET SEGMENT, 2007-2014 ($ MILLIONS) 102

TOTAL GLOBAL MARKET AND PERCENT DISTRIBUTION BY SELECTED GENETIC DISORDER 102

TABLE 59 GLOBAL GENETIC DISORDER PRODUCT REVENUES BY DISORDER THROUGH 2014 ($ MILLIONS) 103

FIGURE 21 GLOBAL GENETIC DISORDER PRODUCT REVENUES BY DISORDER, 2007-2014 ($ MILLIONS) 104

GEOGRAPHICAL ANALYSIS OF GENETIC DISORDER TREATMENTS 104

TABLE 60 GLOBAL GENETIC DISORDER PRODUCT REVENUES BY SELECTED COUNTRY, THROUGH 2014 ($ MILLIONS) 105

FIGURE 22 GLOBAL GENETIC DISORDER PRODUCT REVENUES BY SELECTED COUNTRY, 2007-2014 ($ MILLIONS) 106

MAJOR INDUSTRY PARTICIPANTS BY PRODUCT SEGMENT 106

MAJOR INDUSTRY PARTICIPANTS ...(CONTINUED) 107

TABLE 61 MAJOR INDUSTRY PARTICIPANTS BY PRODUCT SEGMENTS AND SALES GROWTH, THROUGH 2014 ($ MILLIONS) 108

TABLE 61 (CONTINUED) 109

Chapter-8: TECHNOLOGY

PATENT ANALYSIS 110

PATENTS AND GENETICS 110

PATENT EVALUATION BY GENETIC CONDITION 111

TABLE 62 PATENT INFORMATION BY GENETIC CONDITION 112

TABLE 62 (CONTINUED) 113

TABLE 62 (CONTINUED) 114

TABLE 62 (CONTINUED) 115

TABLE 62 (CONTINUED) 116

FIGURE 23 PERCENT OF PATENTS BY GENETIC CONDITION (%) 116

FIGURE 23 (CONTINUED) 117

PATENT EVALUATION BY ASSIGNEE 117

TABLE 63 GENETIC PATENT ASSIGNEES 117

TABLE 63 (CONTINUED) 118

TABLE 63 (CONTINUED) 119

Bristol-Myers Squibb 120

Eli Lilly 120

G. D. Searle & Co./Monsanto Company 120

Genzyme Corp. 120

Purdue Pharma 120

Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. 121

Transkaryotic Therapies 121

Wyeth 121

Chapter-9: COMPANY PROFILES

BAXTER INTERNATIONAL, INC. 122

TABLE 64 BAXTER'S COMPANY REVENUES, 2007-2009 ($ MILLIONS) 123

FIGURE 24 BAXTER'S COMPANY REVENUES, 2007-2009 ($ MILLIONS) 124

BAYER AG 124

TABLE 65 BAYER'S COMPANY REVENUES, 2007-2009 ($ MILLIONS) 125

FIGURE 25 BAYER'S COMPANY REVENUES, 2007-2009 ($ MILLIONS) 126

BIOMARIN PHARMACEUTICAL, INC. 126

TABLE 66 BIOMARIN'S COMPANY REVENUES, 2007-2009 ($ MILLIONS) 127

FIGURE 26 BIOMARIN'S COMPANY REVENUES, 2007-2009 ($ MILLIONS) 127

CANGENE CORP. 128

TABLE 67 CANGENE'S COMPANY REVENUES, 2007-2009* ($ MILLIONS) 129

FIGURE 27 CANGENE'S COMPANY REVENUES, 2007-2009 ($ MILLIONS) 129

CSL BEHRING (CSL LIMITED) 129

TABLE 68 CSL'S COMPANY REVENUES, 2007-2009* ($ MILLIONS) 130

FIGURE 28 CSL'S COMPANY REVENUES, 2007-2009 ($ MILLIONS) 130

ELI LILLY 131

TABLE 69 ELI LILLY'S COMPANY REVENUES, 2007-2009 ($ MILLIONS) 131

FIGURE 29 ELI LILLY'S COMPANY REVENUES, 2007-2009 ($ MILLIONS) 132

ENDO PHARMACEUTICALS 132

TABLE 70 ENDO'S COMPANY REVENUES, 2007-2009 ($ MILLIONS) 133

FIGURE 30 ENDO'S COMPANY REVENUES, 2007-2009 ($ MILLIONS) 134

GENENTECH INC. 134

TABLE 71 GENENTECH AND ROCHE COMPANY REVENUES, 2007-2009 ($ MILLIONS) 135

FIGURE 31 GENENTECH AND ROCHE COMPANY REVENUES, 2007-2009 ($ MILLIONS) 135

GENZYME 135

TABLE 72 GENZYME'S COMPANY REVENUES, 2007-2009 ($ MILLIONS) 136

FIGURE 32 GENZYME'S COMPANY REVENUES, 2007-2009 ($ MILLIONS) 137

H. LUNDBECK A/S 137

TABLE 73 LUNDBECK'S COMPANY REVENUES, 2007-2009 ($ MILLIONS) 138

FIGURE 33 LUNDBECK'S COMPANY REVENUES, 2007-2009 ($ MILLIONS) 138

NOVARTIS INTERNATIONAL AG/SANDOZ 138

NOVARTIS INTERNATIONAL AG/... (CONTINUED) 139

TABLE 74 NOVARTIS' COMPANY REVENUES, 2007-2009 ($ MILLIONS) 140

FIGURE 34 NOVARTIS' COMPANY REVENUES, 2007-2009 ($ MILLIONS) 140

NOVO NORDISK A/S 140

TABLE 75 NOVO NORDISK'S COMPANY REVENUES, 2007-2009 ($ MILLIONS) 141

FIGURE 35 NOVO NORDISK'S COMPANY REVENUES, 2007-2009 ($ MILLIONS) 141

PFIZER, INC/WYETH 142

TABLE 76 PFIZER'S COMPANY REVENUES, 2007-2009 ($ MILLIONS) 143

FIGURE 36 PFIZER'S COMPANY REVENUES, 2007-2009 ($ MILLIONS) 143

SHIRE PLC 143

TABLE 77 SHIRE'S COMPANY REVENUES, 2007-2009 ($ MILLIONS) 144

FIGURE 37 SHIRE'S COMPANY REVENUES, 2007-2009 ($ MILLIONS) 144

Chapter-10: APPENDIX

APPENDIX I: COMPANIES WITH GENETIC RESEARCH PROJECTS 145

ADEONA PHARMACEUTICALS, INC. 145

AEROVANCE, INC. 145

ALDAGEN, INC. 145

AMICUS THERAPEUTICS, INC. 145

AOP ORPHAN PHARMACEUTICALS AG 145

APPLIED GENETIC TECHNOLOGIES CORP. 145

AVI BIOPHARMA 145

AVICENA GROUP, INC. 146

BAYER SCHERING PHARMA AG 146

BIOGEN IDEC 146

BIOMARIN PHARMACEUTICAL INC. 146

COPERNICUS THERAPEUTICS, INC 146

CSL BEHRING 146

EISAI, INC. 146

GILEAD SCIENCES, INC. 147

GLAXOSMITHKLINE PLC 147

HOLLIS-EDEN PHARMACEUTICALS, INC. 147

INSPIRE PHARMACEUTICALS, INC. 147

IPSEN 147

KALOBIOS PHARMACEUTICALS, INC. 147

LANTIBIO, INC. 147

MPEX PHARMACEUTICALS, INC. 148

NEUROSEARCH A/S 148

NORTHFIELD LABORATORIES, INC. 148

NOVO NORDISK A/S 148

PFIZER, INC. 148

PHARMAXIS LTD 148

PROSENSA HOLDING B.V. 149

PROTALIX BIOTHERAPEUTICS 149

PTC THERAPEUTICS, INC. 149

QUATRX PHARMACEUTICALS 149

REGENERX BIOPHARMACEUTICALS, INC. 149

REPROS THERAPEUTICS INC. 149

SANTHERA PHARMACEUTICALS HOLDING AG 150

SHIRE PLC 150

SUCAMPO PHARMACEUTICALS, INC. 150

TRANSAVE, INC. 150

VERTEX PHARMACEUTICALS, INC. 150

APPENDIX II: ASSOCIATIONS AND ORGANIZATIONS 151

ANGELMAN SYNDROME FOUNDATION, INC. 151

CANADIAN SOCIETY FOR MUCOPOLYSACCHARIDE AND RELATED DISEASES, INC. 151

CHILDREN LIVING WITH INHERITED METABOLIC DISEASES (CLIMB) 152

CELIAC DISEASE FOUNDATION 152

CELIAC SPRUE ASSOCIATION 152

CURE CMD (CONGENITAL MUSCULAR DYSTROPHY) 152

CYSTIC FIBROSIS FOUNDATION 152

CYSTIC FIBROSIS RESEARCH, INC. 152

CYSTIC FIBROSIS TRUST 153

CYSTIC FIBROSIS WORLDWIDE 153

DOWN'S SYNDROME ASSOCIATION (UK) 153

FABRY SUPPORT & INFORMATION GROUP 153

GAUCHERS ASSOCIATION (UK) 153

HIDE & SEEK FOUNDATION FOR LYSOSOMAL DISEASE RESEARCH 153

HEMOPHILIA FEDERATION OF AMERICA 154

HUNTINGTON'S ASSOCIATION OF SOUTH AFRICA POSTBOX 4640 154

HUNTINGTON'S DISEASE SOCIETY OF AMERICA 154

HUNTINGTON SOCIETY OF CANADA 154

INTERNATIONAL CENTER FOR FABRY DISEASE 154

INSTITUTO DE ERRORES INNATOS DEL METABOLISMO 155

KLINEFELTER SYNDROME & ASSOCIATES (KS&A) 155

MARCH OF DIMES BIRTH DEFECTS FOUNDATION 155

MUSCULAR DYSTROPHY ASSOCIATION 155

MUSCULAR DYSTROPHY LIMITED (AUSTRALIA) 155

MUSCULAR DYSTROPHY ASSOCIATION OF NEW ZEALAND, INC. 155

MUSCULAR DYSTROPHY CAMPAIGN 156

MUSCULAR DYSTROPHY CANADA 156

MUSCULAR DYSTROPHY IRELAND 156

NATIONAL FOUNDATION FOR CELIAC AWARENESS (NFCA) 156

NATIONAL GAUCHER'S FOUNDATION 156

NATIONAL HEMOPHILIA FOUNDATION 156

NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE (NINDS) 157

NATIONAL MPS SOCIETY (HUNTER SYNDROME) 157

NATIONAL MPS (MUCOPOLYSACCHARIDOSES/ MUCOLIPIDOSES) SOCIETY, INC. 157

NATIONAL ORGANIZATION FOR RARE DISORDERS (NORD) 157

NATIONAL TAY-SACHS AND ALLIED DISEASES ASSOCIATION, INC. 157

PRADER-WILLI SYNDROME ASSOCIATION (UK) 158

THE PRADER-WILLI SYNDROME ASSOCIATION (USA) 158

SICKLE CELL ASSOCIATION 158

SICKLE CELL ASSOCIATION OF ONTARIO 158

SICKLE CELL ASSOCIATION OF TEXAS GULF COAST 158

SICKLE CELL DISEASE ASSOCIATION OF PIEDMONT 158

SICKLE CELL DISEASE FOUNDATION OF CALIFORNIA 158

SOCIETY FOR MUSCULAR DYSTROPHY INFORMATION INTERNATIONAL 159

TURNER'S SYNDROME SOCIETY 159

TURNER SYNDROME SUPPORT SOCIETY (UK) 159

U.S. NATIONAL LIBRARY OF MEDICINE 159

APPENDIX III: INTERNATIONAL LOCATIONS OF GENETIC CLINICS 160

ARGENTINA 160

AUSTRALIA 160

AUSTRIA 161

BAHRAIN 161

BELGIUM 161

BRAZIL 162

CANADA 162

CHILE 163

CZECH REPUBLIC 163

DENMARK 163

FRANCE 163

GERMANY 164

GREECE 164

INDIA 164

ISRAEL 164

ITALY 165

JAPAN 165

NETHERLANDS 165

NEW ZEALAND 166

PORTUGAL 166

RUSSIA 166

SAUDI ARABIA 166

SOUTH KOREA 166

SPAIN 167

TURKEY 167

UNITED KINGDOM 167

To order this report:

Biotechnology Industry: New Developments in Treating Genetic Disorders: The Global Market

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

__________________________ Nicolas Bombourg Reportlinker Email: nbo@reportlinker.com US: (805)652-2626 Intl: +1 805-652-2626

SOURCE Reportlinker
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Reportlinker Adds Pipeline Insight: Systemic Lupus...
S
Reportlinker Adds Preclinical Development of Monoc...